Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions

Ernst, Julia; Klinger-Strobel, Mareike; Arnold, Kathrin; Thamm, Jana; Hartung, Anita; Pletz, Mathias W.; Makarewicz, Oliwia; Fischer, Dagmar

doi:10.1016/j.ejpb.2018.07.025

Cited by 44 publications

(43 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, an enhanced antimicrobial activity of nanoformulated ciprofloxacin at lower drug doses was reported, indicating its promising potential as drug delivery system for CF antimicrobial treatment. Similar results were reported by Ernst et al (2018) who encapsulated tobramycin within PEGcoated PLGA nano (≈230 nm) and micro (≈900 nm) particles and observed an enhance antimicrobial activity, along with a good penetration within mucus and bacterial biofilm in dynamic physiological conditions.…”

Section: Polymeric Nanoparticlessupporting

confidence: 87%

“…Over time, as the colonization advances, PA colonies alter their pattern of gene expression in the CF lung and start producing a mucoid coating made of alginate which protects the bacteria against antibiotics and phagocytosis (Turcios, 2005;O'Sullivan and Freedman, 2009;Gaspar et al, 2013;Bhagirath et al, 2016). In this mucoid form, PA is able to form a biofilm which makes the pathogen up to 100 times more tolerant to antimicrobial treatments (Al-Obaidi et al, 2018;Ernst et al, 2018;Kłodzinska et al, 2018;Lu et al, 2018). Besides, the ability of PA to establish drug resistant biofilms is thought to be facilitated by the hypersecretion of the thick and viscous mucus layer in the CF airway, which provides a low oxygen environment (Moreau-Marquis et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis

Velino

Carella

Adamiano

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cystic fibrosis (CF) is a genetic disease affecting today nearly 70,000 patients worldwide and characterized by a hypersecretion of thick mucus difficult to clear arising from the defective CFTR protein. The overproduction of the mucus secreted in the lungs, along with its altered composition and consistency, results in airway obstruction that makes the lungs susceptible to recurrent and persistent bacterial infections and endobronchial chronic inflammation, which are considered the primary cause of bronchiectasis, respiratory failure, and consequent death of patients. Despite the difficulty of treating the continuous infections caused by pathogens in CF patients, various strategies focused on the symptomatic therapy have been developed during the last few decades, showing significant positive impact on prognosis. Moreover, nowadays, the discovery of CFTR modulators as well as the development of gene therapy have provided new opportunity to treat CF. However, the lack of effective methods for delivery and especially targeted delivery of therapeutics specifically to lung tissues and cells limits the efficiency of the treatments. Nanomedicine represents an extraordinary opportunity for the improvement of current therapies and for the development of innovative treatment options for CF previously considered hard or impossible to treat. Due to the peculiar environment in which the therapies have to operate characterized by several biological barriers (pulmonary tract, mucus, epithelia, bacterial biofilm) the use of nanotechnologies to improve and enhance drug delivery or gene therapies is an extremely promising way to be pursued. The aim of this review is to revise the currently used treatments and to outline the most recent progresses about the use of nanotechnology for the management of CF.

show abstract

Section: Polymeric Nanoparticlessupporting

confidence: 87%

Section: Introductionmentioning

confidence: 99%

Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis

Velino

Carella

Adamiano

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…PLA and PLGA are the most commonly used synthetic polymers for pharmaceutical applications (Campardelli et al 2016;Panyam and Labhasetwar 2003). They are approved materials for biomedical applications by the Food and Drug Administration (FDA) and the European Medicine Agency (Campardelli et al 2016;Ernst et al 2018). Their unique biocompatibility and versatility make them an excellent carrier of drugs in targeting different diseases (Ernst et al 2018).…”

Section: Pla/plga Polymeric Particlesmentioning

confidence: 99%

“…They are approved materials for biomedical applications by the Food and Drug Administration (FDA) and the European Medicine Agency (Campardelli et al 2016;Ernst et al 2018). Their unique biocompatibility and versatility make them an excellent carrier of drugs in targeting different diseases (Ernst et al 2018). The number of commercial products using PLGA or PLA matrices for drug delivery system (DDS) is increasing, and this trend is expected to continue for protein, peptide, and oligonucleotide drugs (Mohamed and van der Walle 2008).…”

Section: Pla/plga Polymeric Particlesmentioning

confidence: 99%

Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery

Emami

Yazdi

2019

J. Pharm. Investig.

View full text Add to dashboard Cite

Background Pulmonary route is an attractive target for both systemic and local drug delivery, with the advantages of a large surface area, rich blood supply, and absence of first-pass metabolism. Numerous polymeric micro/nanoparticles have been designed and studied for controlled and targeted drug delivery to the lung. Area covered Among the natural and synthetic polymers for polymeric particles, poly(lactic acid) (PLA) and poly(lacticco-glycolic acid) (PLGA) have been widely used for the delivery of anti-cancer agents, anti-inflammatory drugs, vaccines, peptides, and proteins because of their highly biocompatible and biodegradable properties. This review focuses on the characteristics of PLA/PLGA particles as carriers of drugs for efficient delivery to the lung. Furthermore, the manufacturing techniques of the polymeric particles, and their applications for inhalation therapy were discussed. Expert opinion Compared to other carriers including liposomes, PLA/PLGA particles present a high structural integrity providing enhanced stability, higher drug loading, and prolonged drug release. Adequately designed and engineered polymeric particles can contribute to a desirable pulmonary drug delivery characterized by a sustained drug release, prolonged drug action, reduction in the therapeutic dose, and improved patient compliance.

show abstract

“…. ), whose degradation rate will control, along with other factors, the drug release rate [2,90]. Due to the limited drug loading capacity of these systems relative to the high dose of antibiotics needed to kill bacteria, repeat administrations (perhaps once or twice a week) should still be required with these systems.…”

Section: Control Of the Fq Release Rate Using Particulate Systemsmentioning

confidence: 99%

Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones

Brillault

Tewes

2020

Pharmaceutics

View full text Add to dashboard Cite

Pulmonary drug delivery is a promising strategy to treat lung infectious disease as it allows for a high local drug concentration and low systemic side effects. This is particularly true for low-permeability drugs, such as tobramycin or colistin, that penetrate the lung at a low rate after systemic administration and greatly benefit from lung administration in terms of the local drug concentration. However, for relatively high-permeable drugs, such as fluoroquinolones (FQs), the rate of absorption is so high that the pulmonary administration has no therapeutic advantage compared to systemic or oral administration. Formulation strategies have thus been developed to decrease the absorption rate and increase FQs’ residence time in the lung after inhalation. In the present review, some of these strategies, which generally consist of either decreasing the lung epithelium permeability or decreasing the release rate of FQs into the epithelial lining fluid after lung deposition, are presented in regards to their clinical aspects.

show abstract

Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions

Cited by 44 publications

References 50 publications

Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis

Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis

Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery

Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones

Contact Info

Product

Resources

About